Zinc Sulfate
Formulations: - Oral > Solid > dispersible tablet: 20 mg (scored) Indications: - Diarrhoea Source: EML workbook import
MOQ: 1
Price on request
New Arrivals
Fresh additions to the Afya Chain catalogue, ready for discovery and procurement.
New Arrivals (Showing 48 out of 662)
Bromocriptine
Indications: - Other specified benign neoplasm of endocrine glands Source: EML workbook import
MOQ: 1
Price on request
Cabergoline
Formulations: - Oral > Solid > tablet: 0.5 mg; 1 mg Indications: - Other specified benign neoplasm of endocrine glands Source: EML workbook import
MOQ: 1
Price on request
Octreotide
Formulations: - Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate) Indications: - Acromegaly or pituitary gigantism Source: EML workbook import
MOQ: 1
Price on request
Ansuvimab
Formulations: - Parenteral > General injections > IV: 400 mg powder for injection Indications: - Ebola virus disease Source: EML workbook import
MOQ: 1
Price on request
Atoltivimab + Maftivimab + Odesivimab
Formulations: - Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial Indications: - Ebola virus disease Source: EML workbook import
MOQ: 1
Price on request
Zoledronic Acid
Formulations: - Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle Indications: - Osteogenesis imperfecta - Malignant neoplasm metastasis in bone or bone marrow Source: EML workbook import
MOQ: 1
Price on request
Deferasirox
Formulations: - Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg Oral > Solid > tablet: 90 mg; 180 mg; 360 mg Indications: - Other specified sickle cell disorders or other haemoglobinopathies - Thalassaemias Source: EML workbook import
MOQ: 1
Price on request
Deferiprone
Indications: - Other specified sickle cell disorders or other haemoglobinopathies - Thalassaemias Source: EML workbook import
MOQ: 1
Price on request
Entecavir
Formulations: - Oral > Liquid: 0.05 mg per mL Oral > Solid: 0.5 mg; 1 mg Indications: - Chronic hepatitis B Source: EML workbook import
MOQ: 1
Price on request
Ledipasvir + Sofosbuvir
Formulations: - Oral > Solid: 90 mg + 400 mg tablet Indications: - Chronic hepatitis C Source: EML workbook import
MOQ: 1
Price on request
Ribavirin
Formulations: - Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg Indications: - Chronic hepatitis C Source: EML workbook import
MOQ: 1
Price on request
Sign Up to Our Newsletter→
Ready to amplify your rewards? Drop your email and we'll be in touch soon.